Emerging cases of mucormycosis under COVID ‐19 pandemic in India: Misuse of antibiotics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emerging cases of mucormycosis under COVID ‐19 pandemic in India: Misuse of antibiotics

Published:2021-07-29 Issue:7 Volume:82 Page:880-882
ISSN:0272-4391
Container-title:Drug Development Research
language:en
Short-container-title:Drug Dev Res

Author:

Gupta Gaurav¹^ORCID,S. Roshan²,Singh Yogendra³,Thangavelu Lakshmi⁴,Singh Sachin Kumar⁵,Dureja Harish⁶,Chellappan Dinesh Kumar⁷,Dua Kamal⁸

Affiliation:

1. School of Pharmacy Suresh Gyan Vihar University Jaipur India

2. Deccan School of Pharmacy Osmania University Hyderabad India

3. Department of Pharmacology, Maharishi Arvind College of Pharmacy Ambabari Circle Jaipur India

4. Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical Sciences Saveetha University Chennai India

5. School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India

6. Faculty of Pharmaceutical Sciences Maharshi Dayanand University Rohtak India

7. Department of Life Sciences, School of Pharmacy International Medical University Kuala Lumpur Malaysia

8. Discipline of Pharmacy, Graduate School of Health University of Technology Sydney Ultimo New South Wales Australia

Publisher

Wiley

Subject

Drug Discovery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.21862

Reference17 articles.

1. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis

2. COVID-19 lockdowns show reduced pollution on snow and ice in the Indus River Basin

3. Tea Bioactive Modulate Innate Immunity: In Perception to COVID-19 Pandemic

4. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

5. Covid-19: India sees record deaths as “black fungus” spreads fear

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review;Frontiers in Immunology;2023-09-25

2. Knowledge and awareness of COVID-19–associated mucormycosis among doctors in a tertiary care center;Indian Journal of Ophthalmology;2023-05

3. DETECTION OF RISK FACTORS AND PATIENT CHARACTERISTICS ASSOCIATED WITH MUCORMYCOSIS TO DESIGN SCREENING TOOLS HELPFUL IN PREVENTING ADVERSITIES AT PRIMARY CARE LEVEL: A CASE CONTROL STUDY;INDIAN JOURNAL OF APPLIED RESEARCH;2022-12-01

4. Practice Guideline on Prevention, Diagnosis, and Treatment of Rhino-Orbito-Cerebral Mucormycosis in the COVID-19 Area: A Consensus of Iranian Experts;Archives of Clinical Infectious Diseases;2022-09-28

5. COVID ‐19‐associated facial cutaneous mucormycosis superinfection: A potentially life‐threatening disease;Clinical Case Reports;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3